Page 8 - Rituximab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rituximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rituximab Today - Breaking & Trending Today

Similar Overall Survival, Shorter Progression-Free Survival With Rituximab Biosimilar in Patients with DLBCL vs Originator

Authors of a single-center, real-world study in Turkey found that patients with diffuse large B-cell lymphoma (DLBCL) who received a rituximab biosimilar had similar overall survival as patients who received the originator. However, progression-free survival was longer in the originator group. ....

International Prognostic Index , Eastern Cooperative Oncology Group , Rituximab Biosimilars ,

BTK Inhibitors for Treatment of CLL

Lori A. Leslie, MD, an expert on chronic lymphocytic leukemia, provides a comprehensive overview of BTK inhibitors used in the treatment of CLL. ....

Gloria Leslie , Chronic Lymphocytic Leukemia , Bruton Tyrosine Kinase Inhibitors , Btk Inhibitors , Targeted Therapies , Btk Inhibition , Resonate 2 , Relapsed Refractory Cll , Elevate Tn , Sequoia Trial ,

Dr Epstein-Peterson on the Treatment of Transplant-Eligible and -Ineligible Patients with MCL

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible. ....

Zachary Epstein Peterson , Memorial Sloan Kettering Cancer Center , Updates In Mantle Cell Lymphoma , Patients With Tp53 Mutated Mcl , Transplant Eligible , Transplant Ineligible , Autologous Stem Cell Transplant ,

Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Dr. Reddy s Laboratories Ltd has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL RI, for filing in highly regulated markets such as the United States, Europe and other regions. ....

United States , Fresenius Kabi , Jayanth Sridhar , European Union , Reddy Laboratories Ltd , Reddy Laboratories , Biologics License Application , Marketing Authorisation Application , Global Head , Laboratories Limited ,

Dr Reddy's Completes Clinical Trials Of Rituximab For Rheumatoid Arthritis

Hyderabad: Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL RI, for filing in highly regulated markets such as the United States, Europe and other regions. ....

United States , Andhra Pradesh , Fresenius Kabi , Jayanth Sridhar , European Union , Reddy Laboratories Ltd , Laboratories Ltd , Biologics License Application , Marketing Authorisation Application , Global Head , Low Tumour Burden Follicular , Global Healthcare Issues Can Only , Solved With Multilateral Cooperation , Dr Reddy 039 S , Clinical Trials , Rheumatoid Arthritis , Dr Reddys Laboratories ,